Le Lézard
Classified in: Health
Subject: TRI

Genetic Treatment for Blindness May Soon be Reality



NEW ORLEANS, Nov. 10, 2017 /PRNewswire-USNewswire/ -- Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.

AAO Logo (PRNewsFoto/American Academy of Ophthalmology)

Patients in the study had a condition called Leber congenital amaurosis (LCA), which begins in infancy and progresses slowly, eventually causing complete blindness. This new, first-of-its-kind gene therapy is currently under review by the U.S. Food and Drug Administration for potential approval this year. There are currently no treatments available for inherited retinal diseases.

Ophthalmologist Stephen R. Russell, M.D., of the University of Iowa, is one of the lead researchers for this pioneering treatment. Data from the first randomized, controlled, phase 3 study showed that 27 of 29 treated patients (93 percent) experienced meaningful improvements in their vision, enough that they could navigate a maze in low to moderate light. They also showed improvement in light sensitivity and peripheral vision, which are two visual deficits these patients experience.

Approval could open the door for other gene therapies that could eventually treat the more than 225 genetic mutations known to cause blindness. It could be applied to retinitis pigmentosa, another inherited retinal disease caused by a defective gene. Or in the future, gene therapy could possibly provide key proteins needed to restore vision in more common diseases such as age-related macular degeneration.

LCA is rare, affecting about 1 in 80,000 individuals. It can be caused by one or more of 19 different genes. The treatment, called voretigene neparvovec (Luxturna, Spark Therapeutics), involves a genetically modified version of a harmless virus. The virus is modified to carry a healthy version of the gene into the retina. Doctors inject billions of modified viruses into both of a patient's eyes.

Treatment doesn't restore normal vision. It does, however, allow patients to see shapes and light, allowing them to get around without a cane or a guide dog. It is unclear how long the treatment will last, but so far, most patients have maintained their vision for two years.

More than 200 patients with LCA have participated in gene therapy trials since 2007.
However, no gene therapy has gotten this close to FDA approval for retinal disease or any other eye disease. In October, an advisory committee to the FDA unanimously endorsed the treatment. The FDA isn't obligated to follow the recommendations of its advisory committees, but it usually does. The agency is expected to make its decision no later than January 2018.

About the American Academy of Ophthalmology
The American Academy of Ophthalmology is the world's largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart® program provides the public with the most trusted information about eye health. For more information, visit aao.org.

SOURCE American Academy of Ophthalmology


These press releases may also interest you

at 20:00
Lori Davison, Vice President, Brand Strategy & Communications at SickKids Foundation has been named Canada's 2017 Marketer of the Year by the Canadian Marketing Association (CMA). For her relentless commitment to propel...

at 18:15
Samumed is a leader in biotech research for regenerative medicine - that also happens to be the most valued biotech startup in the world. As Samumed added more people to its team, and embarked on more ambitious and expensive projects, the CFO of...

at 16:11
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious...

at 16:03
VANC Pharmaceuticals Inc. ("VANC" or the "Company") announces today the intention to launch the INSTI HIV rapid point-of-care test in Ontario with United Pharma Group (UPG) to coincide with World AIDS Day on December 1, 2017. This represents the...

at 13:15
The "Cell Harvesting System Market Analysis By Application (Umbilical Cord, Bone marrow, Peripheral Blood, Adipose Tissue), By End Use (Hospitals, Clinics, R&D Centers), And Segment Forecasts, 2014 - 2025" report has been added to Research and...

at 13:01
Sangamo Therapeutics, Inc.  announced today that the Compensation Committee of the Company's Board of Directors approved the grant effective on November 22, 2017 of inducement stock options to purchase a total of 164,000 shares of common stock to...




News published on 10 november 2017 at 18:11 and distributed by: